Not-for-Profit Does Not Mean No Profit

Understanding the Economics of Tissue Banks

In the first article in this series, we followed the journey of a donated tissue—from donor consent through recovery, testing, processing, and distribution. The goal was to answer a simple question:

If the tissue is donated, why does it cost anything at all?

The answer is that hospitals are not paying for the tissue itself. They are paying for the infrastructure required to make that tissue safe, compliant, traceable, and usable in modern medicine.

But that explanation leads directly to a second, more nuanced question—one that often comes up in hospital value analysis committees and supply chain discussions:

If many tissue banks are not-for-profit organizations, why are grafts still expensive—and does nonprofit versus for-profit really matter?

Hospitals, in particular, are often some of the most vocal stakeholders in this debate. Many express a preference for working with not-for-profit tissue banks, based on the belief that the model is more aligned with the spirit of donation.

That instinct is understandable—but the reality is more complex.

What “Not-for-Profit” Actually Means

Many of the largest tissue banks in the United States operate as nonprofit organizations. The term itself, however, is frequently misunderstood.

Not-for-profit does not mean no profit.

A nonprofit organization can—and must—generate revenue in excess of its operating costs. If it doesn’t, it cannot sustain operations, invest in infrastructure, or continue serving patients.

Like any business, if a tissue bank consistently operates at a loss, it will not be around very long.

The distinction is not whether profit exists. The distinction is what happens to it.

• In a for-profit model, surplus revenue is distributed to shareholders or owners

• In a not-for-profit model, surplus revenue is reinvested into the organization’s mission

In tissue banking, that reinvestment often supports:

• expansion of donor recovery programs

• investment in processing and sterilization technologies

• regulatory and compliance infrastructure

• research and clinical studies

• surgeon education and training

• public awareness and donation initiatives

  
  

So while nonprofit tissue banks absolutely generate surplus revenue, that capital is typically directed back into the system rather than extracted from it.

The Balance Between Sustainability and Mission

There is an important tension at the center of the tissue banking ecosystem.

On one end of the spectrum, an organization must be financially viable. Without margin, there is no ability to invest, grow, or even maintain compliance.

On the other end, tissue banking is fundamentally built on a human gift—one that carries ethical weight.

Organizations that focus solely on maximizing profit can risk losing sight of that reality.

This is not limited to tissue banks themselves. It can extend to:

• for-profit processors

• private-label tissue products marketed by device companies

• commercial organizations that position allografts alongside standard medical devices

  
  

When tissue is viewed purely through a commercial lens, it can begin to look like any other SKU—something to be priced, bundled, and optimized for margin.

That approach can create discomfort among hospitals and clinicians who remain closely connected to the donor aspect of the system.

At the same time, it is equally important to recognize that financial discipline and operational efficiency are not inherently negative. They are necessary to sustain a system of this scale.

The reality is that tissue banking exists in a space where mission and margin must coexist.

Tissue Banks Operate More Like Biologics Manufacturers Than Donation Programs

Another reason costs are often misunderstood is that tissue banking is frequently viewed as an extension of organ donation.

In reality, the operational model more closely resembles biologic manufacturing combined with healthcare logistics.

A modern tissue bank typically includes:

• donor screening and medical review teams

• infectious disease testing laboratories

• surgical recovery operations

• clean-room processing facilities

• sterilization and preservation infrastructure

• regulatory and quality assurance departments

• storage and inventory management systems

• distribution networks

And importantly:

• sales organizations

• marketing teams

• customer service and field support

These commercial functions are often overlooked in discussions about cost, but they can represent significant headcount and operational expense—particularly for organizations that maintain direct relationships with hospitals and surgeons.

Hospitals do not just receive a product. They receive:

• inventory management support

• case coverage and logistics coordination

• product education and training

• customer service infrastructure

  
  

All of these functions contribute to the overall cost structure.

Where Revenue Actually Comes From

Tissue banks do not charge for the tissue itself. Instead, they charge processing and distribution fees.

Those fees must cover the full lifecycle of the graft, including:

• donor identification and authorization

• donor screening and clearance

• recovery operations or procurement costs

• testing and quarantine

• processing and sterilization

• storage and inventory management

• regulatory compliance

• sales, marketing, and customer support

• distribution logistics

  
  

In many cases, if a tissue bank does not perform its own recovery, it must purchase recovered tissue from an external organization. This is often where the cost structure begins.

From that point forward, every step adds cost before a graft ever reaches a hospital.

Why the Model Persists

From the outside, it can be tempting to simplify the system:

“If the tissue is donated, shouldn’t the costs be minimal?”

But when viewed through the full lens of the process, the answer becomes clearer.

The modern tissue banking system is designed to ensure:

• patient safety

• regulatory compliance

• donor traceability

• product consistency

• nationwide availability

  
  

Achieving those goals requires a level of infrastructure that is both complex and expensive.

Whether the organization is nonprofit or for-profit, those underlying requirements do not change.

A System Built on Both Trust and Economics

At its core, tissue banking operates at the intersection of two realities:

1. A deeply human act of donation

2. A highly regulated, industrial-scale medical system

Hospitals sit in the middle of this intersection. They must balance cost, quality, ethics, and clinical outcomes when choosing tissue suppliers.

Understanding how tissue banks operate—and how they sustain themselves financially—is essential to making informed decisions within that system.

What Happens During and Immediately After Recovered?

In the next article in this series, we will examine one of the least visible—and most resource-intensive—steps in tissue banking.

Each donor must undergo a rigorous eligibility determination process involving:

• detailed medical and social history review

• behavioral risk assessment

• infectious disease testing

• physician evaluation

• extensive regulatory documentation

  
  

This process often involves large teams and generates hundreds of pages of records for a single donor.

It is also one of the most significant hidden cost drivers in the entire system.

In the next installment, we will take a deeper look at donor clearance—and why this step alone helps explain much of the cost behind every allograft used in surgery.